CD55 / DAF recombinant protein

Recombinant Human CD55 / DAF Protein (His tag)

Cat. Num. AAA2546529

• Gene Names: CD55; CR; TC; DAF; CROM
• Purity: > 95 % as determined by SDS-PAGE
• Synonyms: CD55 / DAF; Recombinant Human CD55 / DAF Protein (His tag); RP11-357P18.1; CR; CROM; DAF; TC; CD55 / DAF recombinant protein

• Host: Human Cells
• Purity/Purification: > 95 % as determined by SDS-PAGE
• Form/Format: Lyophilized from sterile PBS, pH 7.4
• Sequence Length: 381

• Application Notes: The secreted recombinant human CD55 consists of 330 amino acids and has a predicted molecular mass of 36.5 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhCD55 is approximately 55-60 kDa due to glycosylation.
• Predicted N Terminal: Asp 35
• Endotoxin: < 1.0 EU per mug of the protein as determined by the LAL method
• Preparation and Storage: Samples are stable for up to twelve months from date of receipt at -70 degree C

SDS-PAGE

Related Product Information for CD55 / DAF recombinant protein

Background: CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. It is a major regulator of the alternative and classical pathways of complement activation and is expressed on all serum-exposed cells. CD55 is physiologically acting as an inhibitor of the complement system, but is also broadly expressed in malignant tumours. DAF seems to exert different functions beyond its immunological role such as promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility. It is commonly hijacked by invading pathogens, including many enteroviruses and uropathogenic Escherichia coli, to promote cellular attachment prior to infection. This 70-75 kDa glycoprotein CD55 containing four SCR modules is involved in the regulation of the complement cascade. It inhibits complement activation by suppressing the function of C3/C5 convertases, thereby limiting local generation or deposition of C3a/C5a and membrane attack complex (MAC or C5b-9) production. DAF has been identified as a ligand for an activation-associated, seven-transmembrane lymphocyte receptor, CD97, which is a receptor mediating attachment and infection of several viruses and bacteria. In addition, it has been shown that DAF regulates the interplay between complement and T cell immunity in vivo, and thus may be implicated in immune and tumor biology.

Description: A DNA sequence encoding the human CD55 precursor (NP_000565.1) (Met 1-Ser 353) was expressed, with a C-terminal polyhistidine tag.

NCBI and Uniprot Product Information

• NCBI GI #: 10835143
• NCBI GeneID: 1604
• NCBI Accession #: NP_000565.1
• NCBI GenBank Nucleotide #: NM_000574.4
• UniProt Accession #: P08174; P09679; P78361; Q14UF2; Q14UF3; Q14UF4; Q14UF5; Q14UF6; B1AP14; D3DT83; D3DT84; E7ER69
• Molecular Weight: 59,038 Da
• NCBI Official Full Name: complement decay-accelerating factor isoform 1 preproprotein
• NCBI Official Synonym Full Names: CD55 molecule (Cromer blood group)
• NCBI Official Symbol: CD55
• NCBI Official Synonym Symbols: CR; TC; DAF; CROM
• NCBI Protein Information: complement decay-accelerating factor
• UniProt Protein Name: Complement decay-accelerating factor
• UniProt Gene Name: CD55
• UniProt Synonym Gene Names: CR; DAF

NCBI Description

This gene encodes a glycoprotein involved in the regulation of the complement cascade. Binding of the encoded protein to complement proteins accelerates their decay, thereby disrupting the cascade and preventing damage to host cells. Antigens present on this protein constitute the Cromer blood group system (CROM). Alternative splicing results in multiple transcript variants. The predominant transcript variant encodes a membrane-bound protein, but alternatively spliced transcripts may produce soluble proteins. [provided by RefSeq, Jul 2014]

Uniprot Description

This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade.